Abstract

The present invention addresses the problem of providing a pharmaceutical composition comprising l-menthol at 6 mass% or more and a lower alcohol at 20 mass% or less, the pharmaceutical composition demonstrating improved solubility of l-menthol. The present invention provides a pharmaceutical composition containing: (A) l-menthol at 6 mass% or more; (B) a lower alcohol at 20 mass% or less; (C) at least one selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof; (D) a polyoxyethylene hydrogenated castor oil; and (E) at least one nonionic surfactant selected from the group consisting of polyoxyethylene sorbitan fatty acid esters and polyethylene glycol fatty acid esters.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 9/06 - OintmentsBases therefor
• A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention addresses the problem of providing a bitterness-masked pharmaceutical composition that contains at least one selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof. The present invention provides a pharmaceutical composition comprising: at least one selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof; a sugar alcohol; and a compound including at least one metal selected from the group consisting of alkali metals and alkaline earth metals.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 9/08 - Solutions
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

A solid preparation according to the present invention contains (A) at least one selected from the group consisting of loxoprofen, a salt thereof and hydrates thereof, (B) at least one selected from the group consisting of tranexamic acid and a salt thereof, and (C) at least one selected from the group consisting of magnesium oxide, glycine, erythritol, and caffeine, and is in the form of a tablet or a pill. The solid preparation satisfies a dissolution rate of 60% or more for the component (A) at the 15-minute mark in a dissolution test, and has a hardness of 50 N or more.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

A solid pharmaceutical preparation according to the present invention comprises: (A) at least one substance selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof; (B) at least one substance selected from the group consisting of tranexamic acid and salts thereof; and (C) at least substance selected from the group consisting of magnesium oxide, glycine, erythritol, and caffeine, said solid pharmaceutical preparation being in the form of a tablet or pill, wherein at the 15-minute point in an elution test, the elution rate of the component (A) is not less than 60%.

IPC Classes  ?

• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 47/02 - Inorganic compounds
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

A liquid oral composition containing component (a): copper gluconate, component (b): zinc chloride, and component (c): sodium L-aspartate.

IPC Classes  ?

• A61K 8/365 - Hydroxycarboxylic acidsKetocarboxylic acids
• A61K 8/27 - ZincCompounds thereof
• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses

Abstract

The purpose of the present invention is to provide a pharmaceutical composition that improves the anti-inflammatory effect of loxoprofen. The present invention provides a pharmaceutical composition comprising: at least one selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof; and at least one selected from the group consisting of diclofenac, naproxen, salts thereof, and hydrates thereof.

IPC Classes  ?

• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The solid preparation contains: component (A): at least one selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof; component (B): anhydrous calcium hydrogen phosphate; and component (C): granules containing silicon dioxide; and includes component (D): a disintegrant inside the granules and/or outside the granules.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 9/26 - Discrete particles in supporting matrix
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 47/02 - Inorganic compounds
• A61K 47/04 - Non-metalsCompounds thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention provides a solid composition that contains: (a) bromhexine or a salt thereof; (b) a nonionic surfactant; and (c) a compound selected from the group consisting of a vitamin-based antioxidant, a phenolic antioxidant, meloxicam and acetaminophen (solid compositions containing ibuprofen, clemastine fumarate, dihydrocodeine phosphate, noscapin, dl-methylephedrine hydrochloride, anhydrous caffeine, bromhexine hydrochloride, tranexamic acid, riboflavin, benfotiamine, ascorbic acid, hesperidin, D-mannitol, low-substituted hydroxypropyl cellulose, crystalline cellulose, hydroxypropyl cellulose, polyoxyethylene hardened castor oil 60, hypromellose, talc, hydroxypropyl cellulose, and light anhydrous silicic acid are excluded).

IPC Classes  ?

• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 11/10 - Expectorants
• A61P 11/14 - Antitussive agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A method for producing a solid preparation according to the present invention is for producing a solid preparation which contains (A) at least one substance that is selected from the group consisting of loxoprofen, salts thereof, and hydrates of loxoprofen and the salts, and (B) at least one substance that is selected from the group consisting of tranexamic acid and salts thereof. The method includes a wet granulation step for obtaining granules by supplying water to a starting material powder that contains the components (A) and (B). In the wet granulation step, X is adjusted so as to satisfy 0.20 ≤ Ig ≤ 0.99, wherein X is the addition rate of water to be supplied, PL is the plastic limit water addition rate of the starting material powder, and Ig is the granulation index that is represented by X/PL.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

This skin-improving agent contains the following components (A) to (C). (A) At least one selected from the group consisting of L-cysteine, a derivative thereof and a salt thereof. (B) At least one selected from the group consisting of ascorbic acid, a derivative thereof, and a salt thereof. (C) One or more selected from the group consisting of vitamin B5, vitamin B6, vitamin B2, vitamin E, gamma oryzanol, dong quai and an extract thereof.

IPC Classes  ?

• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 8/63 - SteroidsDerivatives thereof
• A61K 8/67 - Vitamins
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/4415 - Pyridoxine, i.e.vitamin B6
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 36/232 - Angelica
• A61P 17/00 - Drugs for dermatological disorders
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin

Abstract

Provided is a skin-improving agent comprising the component (A1) or (A2) and the component (B1) or (B2) mentioned below. (A1) At least one component selected from the group consisting of Japanese angelica root and an extract thereof; (A2) gamma oryzanol; (B1) one or more components selected from the group consisting of vitamin B5 compounds, vitamin B6 compounds, vitamin B2 compounds, vitamin B3 compounds, L-cysteine and derivatives thereof, and salts of L-cysteine and the derivatives, ascorbic acid and derivatives thereof, and salts of ascorbic acid and the derivatives, and vitamin E compounds; and (B2) one or more components selected from the group consisting of vitamin B5 compounds, vitamin B6 compounds, L-cysteine and derivatives thereof, and salts of L-cysteine and the derivatives, ascorbic acid and derivatives thereof, and salts of ascorbic acid and the derivatives, and vitamin B2 compounds.

IPC Classes  ?

• A61K 36/232 - Angelica
• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 8/63 - SteroidsDerivatives thereof
• A61K 8/67 - Vitamins
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 31/4415 - Pyridoxine, i.e.vitamin B6
• A61P 17/00 - Drugs for dermatological disorders
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin

Abstract

This solid preparation contains component (A): at least one substance selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof, and component (B): at least one substance selected from the group consisting of tranexamic acid and salts thereof, and is such that in an X-ray diffraction pattern measured using Cu-Kα rays, there is no peak in at least three of the following five ranges of diffraction angle 2θ: 7.3 ± 0.1, 11.0 ± 0.1, 19.1 ± 0.1, 22.2 ± 0.1, and 24.8 ± 0.1.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention addresses the problem of providing a novel technology in which loxoprofen and/or a salt thereof are used to prevent pharyngitis and recover a water-swallowing reflex. The present invention provides a pharmaceutical composition which has a pharyngitis inhibitory action and which includes at least one selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 11/04 - Drugs for disorders of the respiratory system for throat disorders
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention provides a skin quality improver containing Bacillus coagulans as an active ingredient (the skin quality improver excluding (1) and (2) below). (1) A beautifying food or beverage containing star fruit tea extract, Bacillus coagulans, fermented collagen peptides, vitamin C, and vitamin B6. (2) A beautifying food containing Bacillus coagulans, ceramides, and soybean peptides.

IPC Classes  ?

• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61P 31/04 - Antibacterial agents
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/08 - Anti-ageing preparations
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The present invention addresses the problem of providing an oral composition that has an excellent ability to form an effective bacterial flora in the oral cavity, is capable of preventing the occurrence of dental caries or periodontal disease caused by oral pathogens or capable of treating such a disease, and capable of also preventing or curing halitosis. The present invention provides an oral composition containing Lactobacillus sporogenes.

IPC Classes  ?

• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses
• C12N 1/20 - BacteriaCulture media therefor

Abstract

The present invention provides a solid composition containing nicotinamide, ascorbic acid, tranexamic acid, and L-cysteine.

IPC Classes  ?

• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A23L 5/00 - Preparation or treatment of foods or foodstuffs, in generalFood or foodstuffs obtained therebyMaterials therefor
• A23L 33/15 - Vitamins
• A23L 33/175 - Amino acids
• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61K 8/67 - Vitamins
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/18 - Antioxidants, e.g. antiradicals
• A61P 39/06 - Free radical scavengers or antioxidants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61Q 19/00 - Preparations for care of the skin

Abstract

This liquid composition for oral use comprises component (a), which is at least one selected from the group consisting of tranexamic acid and salts thereof, and a component (b), which is a perfume, and fulfils at least one of conditions 1 and 2 below. Condition 1 is that the liquid composition further comprises a component (c), which is a surfactant having an HLB value of 13.0-20.0, where the mass ratio (c)/((a)+(b)) is at least 3.5. Condition 2 is that the color difference ΔE* is 0.0-2.5.

IPC Classes  ?

• A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
• A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
• A61K 8/19 - Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses

Abstract

Provided is a loxoprofen-containing solid preparation for external use, that is excellent in solubility during production. The present invention provides a solid preparation for external use containing: loxoprofen, at least one selected from the group consisting of salts thereof and hydrates thereof, a saturated fatty acid salt, a polyoxyethylene-cured castor oil, and a polyethylene glycol fatty acid ester.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 9/06 - OintmentsBases therefor
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The present invention addresses the problem of providing a skin external preparation, that contains a heparinoid and at least one selected from the group consisting of loxoprofen, a salt thereof and hydrates of the same, and that has improved stability. According to the present invention, provided is a skin external preparation that contains a heparinoid and at least one selected from the group consisting of loxoprofen, a salt thereof and hydrates of the same and that has excellent stability.

IPC Classes  ?

• A61K 31/727 - HeparinHeparan
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/737 - Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/14 - VasoprotectivesAntihaemorrhoidalsDrugs for varicose therapyCapillary stabilisers
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 17/16 - Emollients or protectives, e.g. against radiation
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

The present invention addresses the problem of providing: a solid preparation obtained by blending an antacid and one or more types of compound selected from the group consisting of loxoprofen and a salt thereof, said preparation being a stable preparation in which a decrease in the loxoprofen content therein is suppressed; and a method for producing the same. The present invention provides a solid preparation which contains: one or more types of compound selected from the group consisting of loxoprofen and a salt thereof; a compound containing magnesium and/or aluminum; and a hydroxypropyl cellulose.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/20 - Pills, lozenges or tablets
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 47/02 - Inorganic compounds
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Provided is a liquid composition for oral use, which contains a water-soluble copper salt and a water-soluble aluminum salt.

IPC Classes  ?

• A61K 8/365 - Hydroxycarboxylic acidsKetocarboxylic acids
• A61K 8/19 - Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
• A61K 8/26 - AluminiumCompounds thereof
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses

Abstract

The present invention provides a solid composition comprising nicotinic acid amide, ascorbic acid, and tranexamic acid.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 3/02 - Nutrients, e.g. vitamins, minerals
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

To provide an exceptionally transparent composition in which cholesterol can be stably dispersed in an aqueous medium.　Provided is a transparent aqueous composition containing (a) cholesterol, (b) a surfactant having a sterol skeleton, and (c) water, the mass ratio ((b) surfactant having sterol skeleton/(a) cholesterol) of the (b) surfactant having a sterol skeleton to the (a) cholesterol being 4 or greater.

IPC Classes  ?

• A61K 8/63 - SteroidsDerivatives thereof
• A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
• A61K 8/34 - Alcohols
• A61K 8/86 - Polyethers
• A61Q 19/00 - Preparations for care of the skin

Abstract

The present invention addresses the problem of providing a topical skin agent containing a heparinoid and another active ingredient, wherein the storage stability of the heparinoid is improved. According to the present invention, there is provided a topical skin agent containing a heparinoid and loxoprofen or a salt thereof.

IPC Classes  ?

• A61K 31/727 - HeparinHeparan
• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61K 9/70 - Web, sheet or filament bases
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is an oil-in-water emulsion composition having excellent storage stability.　The present invention provides an oil-in-water emulsion composition containing: an oily component that contains (a1) cholesterol, (a2) a higher alcohol, and (a3) a hydrocarbon; a surfactant that contains (b1) polyoxyethylene alkyl ether; and an aqueous component, wherein the content of the component (a1) is 0.7-14 mass% of the total mass of the oily component, and the content of the component (b1) is 0.6-2.8 mass% of the total mass of the emulsion composition.

IPC Classes  ?

• A61P 17/00 - Drugs for dermatological disorders
• A61Q 19/00 - Preparations for care of the skin
• A61K 9/107 - Emulsions
• A61K 8/06 - Emulsions
• A61K 8/31 - Hydrocarbons
• A61K 8/34 - Alcohols
• A61K 8/37 - Esters of carboxylic acids
• A61K 8/63 - SteroidsDerivatives thereof
• A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
• A61K 8/86 - Polyethers
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Abstract

[Problem] To provide a novel face mask. [Solution] A face mask according to the present invention comprising a sheet-shaped base material configured so as to cover at least a part of the face of a user, and a cosmetic composition impregnated into the sheet-shaped base material, wherein: the sheet-shaped base material being provided with a nose cut section through which the nose of the user passes; a length L from the lowest part of the nose cut section to a lower side of the sheet-shaped base material is in a range of 80-100 mm; at the lower side of the sheet-shaped base material, the radius R1 of a curve of a portion intersecting a center perpendicular line of the sheet-shaped base material is in a range of 170-230 mm; and a stringing length of the cosmetic composition is 10 mm or more when the face mask is pulled and removed at a speed of 1200 mm/min.

IPC Classes  ?

• A61Q 19/00 - Preparations for care of the skin
• A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
• A61K 8/34 - Alcohols
• A61K 8/73 - Polysaccharides
• A45D 44/22 - Face shaping devices, e.g. chin strapsWrinkle removers, e.g. stretching the skin

Goods & Services

Cosmetics and toiletries; soaps and detergents; skin whitening essences; skin whitening creams; skin lotions; cream for whitening the skin; cosmetic products for skin care; cosmetics used for skin; non-medicated skin care preparations; cleansing creams; skin washes; shampoos; essential oils; make-up powders; facial beauty masks; lipsticks; bath oils; dentifrices; mint essence (essential oil); perfumery; fragrances; incenses; hand creams. Medicated toiletry preparations; pharmaceutical preparations and substances used to improve freckles and improve chloasma; pharmaceutical preparations and substances used to treat skin containing tranexamic acid and cysteine and vitamin C; pharmaceutical preparations and substances; vitamin preparations and multi-vitamin preparations; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic food adapted for medical purposes; beverages for babies; food for babies; lacteal flour for babies; oiled paper for medical purposes; wrapping wafers for medicine doses; empty capsules for pharmaceuticals; gauze for dressings; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; dental materials, namely materials for stopping teeth, dental wax.

Goods & Services

Cosmetics and toiletries; soaps and detergents; skin whitening essences; skin whitening creams; skin lotions; cream for whitening the skin; cosmetic products for skin care; cosmetics used for skin; non-medicated skin care preparations; cleansing creams; skin washes; shampoos; essential oils; make-up powders; facial beauty masks; lipsticks; bath oils; dentifrices; mint essence (essential oil); perfumery; fragrances; incenses; hand creams. Medicated toiletry preparations; pharmaceutical preparations and substances used to improve freckles and improve chloasma; pharmaceutical preparations and substances used to treat skin containing tranexamic acid and cysteine and vitamin C; pharmaceutical preparations and substances; vitamin preparations and multi-vitamin preparations; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic food adapted for medical purposes; beverages for babies; food for babies; lacteal flour for babies; oiled paper for medical purposes; wrapping wafers for medicine doses; empty capsules for pharmaceuticals; gauze for dressings; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; dental materials, namely materials for stopping teeth, dental wax.

Goods & Services

Cosmetics and toiletries; soaps and detergents; skin whitening essences; skin whitening creams; skin lotions; cream for whitening the skin; cosmetic products for skin care; cosmetics used for skin; non-medicated skin care preparations; cleansing creams; skin washes; shampoos; essential oils; make-up powders; facial beauty masks; lipsticks; bath oils; dentifrices; mint essence (essential oil); perfumery; fragrances; incenses; hand creams. Medicated toiletry preparations; pharmaceutical preparations and substances used to improve freckles and improve chloasma; pharmaceutical preparations and substances used to treat skin containing tranexamic acid and cysteine and vitamin C; pharmaceutical preparations and substances; vitamin preparations and multi-vitamin preparations; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic food adapted for medical purposes; beverages for babies; food for babies; lacteal flour for babies; oiled paper for medical purposes; wrapping wafers for medicine doses; empty capsules for pharmaceuticals; gauze for dressings; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid bandages; breast-nursing pads; dental materials, namely materials for stopping teeth, dental wax.

Goods & Services

Cosmetics and toiletries; soaps and detergents; skin whitening essences; skin whitening creams; skin lotions; cream for whitening the skin; cosmetic products for skin care; cosmetics used for skin; non-medicated skin care preparations; cleansing creams; skin washes; shampoos; essential oils; make-up powders; facial beauty masks; lipsticks; bath oils; dentifrices; mint essence (essential oil); perfumery; fragrances; incenses; hand creams. Pharmaceutical preparations and substances; pharmaceutical preparations and substances used to improve freckles and improve chloasma; pharmaceutical preparations and substances used to treat skin containing tranexamic acid and cystein and vitamin c; vitamin preparations and multi-vitamin preparations; dietary supplements for humans; dietetic beverages adapted for medical purposes, dietetic food adapted for medical purposes; beverages for babies, food for babies; lacteal flour for babies; oiled paper for medical purposes, wrapping wafers for medicine doses, empty capsules for pharmaceuticals, gauze for dressings, eyepatches for medical purposes, ear bandages, menstruation bandages, menstruation tampons, sanitary napkins, sanitary panties, absorbent cotton, adhesive plasters, bandages for dressings, liquid bandages, breast-nursing pads; dental materials, namely materials for stopping teeth, dental wax.

Goods & Services

Cosmetics and toiletries; soaps and detergents; skin whitening essences; skin whitening creams; skin lotions; cream for whitening the skin; cosmetic products for skin care; cosmetics used for skin; non-medicated skin care preparations; cleansing creams; skin washes; shampoos; essential oils; make-up powders; facial beauty masks; lipsticks; bath oils; dentifrices; mint essence (essential oil); perfumery; fragrances; incenses; hand creams. Pharmaceutical preparations and substances; pharmaceutical preparations and substances used to improve freckles and improve chloasma; pharmaceutical preparations and substances used to treat skin containing tranexamic acid and cystein and vitamin C; vitamin preparations and multi-vitamin preparations; dietary supplements for humans; dietetic beverages adapted for medical purposes, dietetic food adapted for medical purposes; beverages for babies, food for babies; lacteal flour for babies; oiled paper for medical purposes, wrapping wafers for medicine doses, empty capsules for pharmaceuticals, gauze for dressings, eyepatches for medical purposes, ear bandages, menstruation bandages, menstruation tampons, sanitary napkins, sanitary panties, absorbent cotton, adhesive plasters, bandages for dressings, liquid bandages, breast-nursing pads; dental materials, namely materials for stopping teeth, dental wax.

Goods & Services

Hair care preparations; hair treatment preparations; hair tonics; hair spray; hair lotions; hair dyes; hair oils; permanent wave preparations; hair bleaches; hair colorants; shampoos; soaps and detergents; dentifrices; cosmetics; cosmetic kits; toiletries; perfumes; essential oils; peppermint oil [perfumery]; medicated soap; cosmetic preparations for eyelashes; eyebrow cosmetics. Medicinal hair growth preparations; pharmaceutical preparations and substances; medicines for human purposes; pharmaceutical preparations and other preparations for destroying vermin, fungicides, herbicides; oiled paper for medical purposes; wrapping wafers for medicine doses; gauze for dressings; capsules for pharmaceutical purposes; eyepatches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid dressings; breast-nursing pads; dental materials; lacteal flour for babies; dietary supplements for humans; dietetic beverages adapted for medical purposes; dietetic food adapted for medical purposes; beverages for babies; food for babies.

Goods & Services

Pharmaceutical preparations and substances; medicines for human purposes; pharmaceutical preparations and other preparations for destroying vermin, fungicides, herbicides; oiled paper for medical purposes; wrapping wafers for medicine doses; gauze for dressings; capsules for pharmaceutical purposes; eye patches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; liquid dressings; breast-nursing pads; dental materials.

Goods & Services

Pharmaceutical preparations and substances (except for mosquito-repellent incenses, sodium salts for medical purposes and medicinal alcoholic beverages); medicines for human purposes; adhesive plasters; bandages for dressings; liquid dressings; gauze for dressings; pledget, namely wisp of cotton thread and yearn, for medical purposes; absorbent wadding; wrapping wafers for medicine doses; sponges for medical purposes; capsules for pharmaceutical purposes; menstruation bandages; lactose for preparing pharmaceutical and veterinary preparations; fungicides, herbicides.

Goods & Services

Soap; disinfectant soap; cleansing milk for toilet purposes; medicated soap; hair cleaners; soap for foot perspiration; deodorant soap; cakes of toilet soap; cakes of soap; antiperspirant soap (sweat prevention); antiperspirant soap (sweat removal); hand soap; shampoos; shampoo soft soap; hair softener; hair conditioner; antimicrobial hand soap; body shampoo; facial cleansing creams; skin whitening creams; hair dyes; cosmetics; facial washing milk; moisturizing face masks.

Goods & Services

Dentifrices and mouthwashes; tooth powder; moistened tooth powder; non-medicated dental rinse; dentifrices in the form of chewing gum; tooth paste.

Abstract

A therapeutic or prophylactic agent for influenza infection, the function mechanism of which is to effectively overcome ATP depletion, said agent comprising diisopropylamine dichloroacetate (DADA), DADA and gluconic acid or a salt thereof, or DADA, gluconic acid or a salt thereof and a vitamin B1 compound.

IPC Classes  ?

• A61K 31/131 - Amines, e.g. amantadine acyclic
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/7012 - Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Disclosed is a tablet containing tranexamic acid, ascorbic acid and L-cysteine, which has excellent stability and is suppressed in discoloration and unpleasant odor. Specifically disclosed is a film-coated tablet that is obtained by providing a tablet, which contains tranexamic acid, ascorbic acid and L-cysteine, with a coating film that contains a polyvinyl alcohol copolymer.

IPC Classes  ?

• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 9/30 - Organic coatings
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61P 17/00 - Drugs for dermatological disorders

Abstract

Provided is a solid pharmaceutical formulation for internal use, having no discoloration and excellent stability, with a formulation that contains tranexamic acid and ascorbic acid. The solid pharmaceutical formulation for internal use is characterized in that the formulation is comprised by adding a polyvinyl alcohol copolymer and/or partially saponified polyvinyl alcohol to the formulation that contains tranexamic acid and ascorbic acid.

IPC Classes  ?

• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/32 - Organic coatings containing solid synthetic polymers
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/4415 - Pyridoxine, i.e.vitamin B6
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61P 17/00 - Drugs for dermatological disorders

Abstract

Disclosed is a solid preparation for oral administration, which comprises tranexamic acid and ascorbic acid, does not undergo discoloration or the like, and therefore meets the requirements for stability. Specifically disclosed is a solid preparation for oral administration, which is characterized by comprising tranexamic acid and ascorbic acid as active ingredients, wherein the active ingredients are separated from each other through a boundary.

IPC Classes  ?

• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 9/30 - Organic coatings
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/4415 - Pyridoxine, i.e.vitamin B6
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

Disclosed is a pharmaceutical composition which is stable and free from discoloration or the like even when tranexamic acid and ascorbic acid are uniformly mixed therein. The pharmaceutical composition containing tranexamic acid and ascorbic acid is characterized in that an organic acid or an antioxidant other than ascorbic acid and tocopherol is additionally contained therein as a stabilizer, and that the components contained in the composition are uniformly mixed therein.

IPC Classes  ?

• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 9/50 - Microcapsules
• A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
• A61K 47/02 - Inorganic compounds
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61P 17/00 - Drugs for dermatological disorders

Goods & Services

Pharmaceutical, veterinary and sanitary preparations; preparations for destroying vermin; fungicides; herbicides; oiled paper for medical purposes; sanitary masks; pharmaceutical wafer; gauze for dressings; empty capsules for pharmaceuticals; eye patches for medical purposes; ear bandages; menstruation bandages; menstruation tampons; sanitary napkins; sanitary panties; absorbent cotton; adhesive plasters; bandages for dressings; collodion for pharmaceutical purposes; breast-nursing pads; dental materials; bracelets for medical purposes; incontinence diapers; mothproofing paper; lactose (milk sugar).

Abstract

An antitussive or expectorant pharmaceutical composition comprising loxoprofen and one or more members selected from caffeine, ephedrine and codeine.

IPC Classes  ?

• A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 11/06 - Antiasthmatics
• A61P 11/10 - Expectorants
• A61P 11/14 - Antitussive agents
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups